Edition:
India

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

27.94USD
10:59pm IST
Change (% chg)

$-0.15 (-0.53%)
Prev Close
$28.09
Open
$28.17
Day's High
$28.52
Day's Low
$27.13
Volume
133,240
Avg. Vol
317,858
52-wk High
$43.98
52-wk Low
$13.51

Select another date:

Thu, Apr 19 2018

BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment

* 5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia

* ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

BRIEF-Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers

* ADAMAS PHARMACEUTICALS SAYS ‍AS OF FEB 28, CO RECEIVED PRESCRIPTIONS FOR GOCOVRI FROM ABOUT 390 DISTINCT PRESCRIBERS - SEC FILING​

BRIEF-Adamas Q4 Loss Per Share $1.27

* ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017

BRIEF-Adamas Announces Proposed Public Offering Of Common Stock

* ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients

* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results

BRIEF-Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals

* Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​ Source text (http://bit.ly/2zY2CVE) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​

* Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​ Source text : (http://bit.ly/2lnW6oI) Further company coverage:

Select another date: